LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer

LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer

BOTHELL, Wash., Feb. 03, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced the appointment of Mark F. Kubik as Chief…

LeonaBio appoints industry veteran Mark F. Kubic as CBO - BioTuesdays

LeonaBio (NASDAQ: LONA) has appointed Mark F. Kubic as chief business officer (CBO) to lead the company’s business development strategy and execution. Mr. Kubik served as a strategic consultant to LeonaBio and played a key role in its December 2025 transformational transaction to acquire rights to the Phase 3 lasofoxifene program for metastatic breast cancer. In a statement, Mark Litton, PhD, president and CEO of LeonaBio, commented, “Mark’s app…